Phaos Tech (NYSE: POAS) stock plunged from $6.46 to $1.06 in a day
Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
20-F
Rhea-AI Filing Summary
Phaos Technology Holdings (Cayman) Limited (POAS) reports on the year ended April 30, 2026 as an early-stage holding company for microscopy equipment operations conducted mainly through its Singapore subsidiary PTPL. The company remains loss-making, with net losses and negative cash flow and its auditors preparing statements on a going-concern basis while management discloses substantial doubt about its ability to continue as a going concern.
Revenue was S$132,077, down from S$167,707 in 2025, and customer concentration is high: the top five customers contributed 81% of revenue in 2026 and the largest customer 38%. Revenue is also geographically concentrated in Asia, primarily Singapore. A loan to PT Neura Integrasi Solusi for biomedical scanning software development has been fully written off by April 30, 2026.
The company had 16,446,750 Class A and 15,125,251 Class B Ordinary Shares outstanding as of April 30, 2026, with a dual class structure giving Class B 20 votes per share and representing 49.94% of total voting rights for the major shareholder. POAS is listed on NYSE American, qualifies as an emerging growth company and foreign private issuer, reports significant share price volatility, material weaknesses in internal controls over financial reporting, and outlines extensive risk factors related to financing, customer and geographic concentration, governance, and potential PFIC status.
Positive
- None.
Negative
- Substantial doubt about going concern: The company discloses that it has incurred recurring operating losses and negative cash flows, needs additional working capital, and that substantial doubt exists about its ability to continue as a going concern.
- Declining revenue and persistent losses: Revenue fell from S$167,707 in 2025 to S$132,077 in 2026, while net losses widened to S$6,157,779 from S$5,137,064, indicating worsening operating performance.
- Full write-off of software development loan: A loan to PT Neura Integrasi Solusi for biomedical scanning software has been fully written off by April 30, 2026, which management states could materially and adversely affect financial condition and results.
